SLS - SELLAS Life Sciences Group, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• SELLAS Life Sciences GAAP EPS of -$0.31
• SELLAS Life Sciences GAAP EPS of -$0.47 misses by $0.18
• SELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-line
• Sellas Life Sciences dips after pricing $20M securities offering
• SELLAS stock slides -32% after launching stock and warrants offering
• SELLAS falls 39% after delaying key milestone for cancer drug
• SELLAS Life Sciences GAAP EPS of -$0.34 beats by $0.05
• Sellas rises as GPS/Keytruda combo shows survival, disease control benefit in ovarian cancer trial
• SELLAS Life Sciences GAAP EPS of -$0.41 misses by $0.02
• SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study
• Sellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapy
• Sellas' GPS, Opdivo combo shows promise in early stage study in type of lung cancer
• Sellas announces topline data for lead asset in Ovarian cancer
• SELLAS Life Sciences GAAP EPS of -$1.05, revenue of $1M
• Sellas Life Sciences gets China regulator nod to start trial of immunotherapy 3D189
• SELLAS Life Sciences plunged 24% on $25M stock offering
• Sellas Life Sciences licenses CDK9 inhibitor from China's GenFleet Therapeutics
• Sellas Life Sciences stock slumps on securities offering
• Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer
• SELLAS Life Sciences' IND application for galinpepimut-S accepted in China